Norfluoxetine hydrochloride
Based on 1 Customer Validation
Norfluoxetine hydrochloride is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine hydrochloride exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine hydrochloride inhibits high-threshold voltage-gated Ca2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine hydrochloride can be used in research related to depression, ischemic stroke, and epilepsy.
For research use only. We do not sell to patients.
- Purity : 99.54%
- CAS No.: 57226-68-3
- Formula: C16H17ClF3NO
- Molecular Weight:331.76
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Calcium Channel Isoforms
More
Biological Activity
Description
In Vitro
Norfluoxetine (0.1-10 μM; 12-24 h) hydrochloride inhibits full-length human TREK-2 channels expressed in Xenopus laevis oocytes with an IC50 of 2.7 μM at +40 mV; inhibition is reduced by TPA and ML335 but not by tetraethylammonium or 2-APB[1].
Norfluoxetine (10-100 μM) hydrochloride reduces single-channel open probability, current amplitude, mean open time, and mean short closed time of truncated human TREK-2 channels reconstituted in lipid bilayers, with increased inhibitory efficacy at voltages above +60 mV, and exhibits similar inhibitory efficacy in high-Po and standard gating modes[1].
Norfluoxetine (10 μM) hydrochloride significantly attenuates nitric oxide and TNF release from lipopolysaccharide-activated primary rat microglia[2].
Norfluoxetine (10-30 μM) hydrochloride reduces protein levels in non-activated primary rat microglia in a dose-dependent manner[2].
Norfluoxetine (10-30 μM) hydrochloride reduces viability of non-activated primary rat microglia in a dose-dependent manner[2].
Norfluoxetine (10 μM) hydrochloride significantly increases the number of dead non-activated primary rat microglia, as measured by live/dead nuclear staining[2].
Norfluoxetine (10 μM) hydrochloride significantly increases the percentage of non-activated primary rat microglia expressing the apoptotic marker cleaved-caspase 3[2].
Norfluoxetine (10-20 μM; 24 h) hydrochloride induces apoptosis in non-activated primary rat microglia by increasing cleaved-caspase 3 and decreasing full-length caspase 3, without altering caspase 8 levels[2].
Norfluoxetine (1-100 μM; 30 s) hydrochloride concentration-dependently inhibits voltage-gated Ca2+ channel-mediated Ba2+ currents in isolated rat cochlear neurons with an EC50 of 20.4 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:non-activated primary rat microglia
-
Concentration:10 and 20 μM
-
Incubation Time:24 h
-
Result:Elevated Cleaved-Caspase 3.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CFLP (male, 23 g)[3]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:s.c.; single dose
-
Result:Increased survival rate, survival duration, and seizure latency significantly at 20 mg/kg compared to pentylenetetrazol-only controls.
Increased combined protection score significantly at 10 mg/kg and 20 mg/kg compared to controls.
Showed no significant differences in anticonvulsant effects compared to fluoxetine at matching doses.
Chemical Information
-
CAS No. 57226-68-3
-
Appearance Solid
-
Molecular Weight 331.76
-
Formula C16H17ClF3NO
-
Color White to off-white
-
SMILES
FC(F)(F)C1=CC=C(OC(C2=CC=CC=C2)CCN)C=C1.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (376.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (762 KB)
- English - EN (762 KB)
- Français - FR (762 KB)
- Deutsch - DE (762 KB)
- Norwegian - NO (762 KB)
- Español - ES (762 KB)
- Swedish - SV (762 KB)
- Italian - IT (762 KB)
- Korean - KR (762 KB)
- Portuguese - PT (762 KB)
-
Handling Instructions (2659 KB)
References
[1]. Proks P, et al. Norfluoxetine inhibits TREK-2 K2P channels by multiple mechanisms including state-independent effects on the selectivity filter gate. The Journal of general physiology. 2021 Aug 02;153(8):e202012812. [Content Brief]
[2]. Dhami KS, et al. Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis. Journal of neurochemistry. 2019 Mar;148(6):761-778. [Content Brief]
[3]. Kecskeméti V, et al. Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies. Brain research bulletin. 2005 Sep 30;67(1-2):126-32. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0142 mL | 15.0711 mL | 30.1423 mL | 75.3557 mL |
| 5 mM | 0.6028 mL | 3.0142 mL | 6.0285 mL | 15.0711 mL | |
| 10 mM | 0.3014 mL | 1.5071 mL | 3.0142 mL | 7.5356 mL | |
| 15 mM | 0.2009 mL | 1.0047 mL | 2.0095 mL | 5.0237 mL | |
| 20 mM | 0.1507 mL | 0.7536 mL | 1.5071 mL | 3.7678 mL | |
| 25 mM | 0.1206 mL | 0.6028 mL | 1.2057 mL | 3.0142 mL | |
| 30 mM | 0.1005 mL | 0.5024 mL | 1.0047 mL | 2.5119 mL | |
| 40 mM | 0.0754 mL | 0.3768 mL | 0.7536 mL | 1.8839 mL | |
| 50 mM | 0.0603 mL | 0.3014 mL | 0.6028 mL | 1.5071 mL | |
| 60 mM | 0.0502 mL | 0.2512 mL | 0.5024 mL | 1.2559 mL | |
| 80 mM | 0.0377 mL | 0.1884 mL | 0.3768 mL | 0.9419 mL | |
| 100 mM | 0.0301 mL | 0.1507 mL | 0.3014 mL | 0.7536 mL |